^
    Back
    Association details:
    Biomarker:KRAS G12D
    Cancer:Lung Cancer
    Drug:Koselugo (selumetinib) (MEK inhibitor) +
    navitoclax (ABT 263) (Bcl2 inhibitor, Bcl-xL inhibitor, Bcl-w inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Cancer Cell
    Title:

    Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models

    Excerpt:
    we assessed the efficacy of combined BCL-XL/MEK inhibition in established KRAS-driven lung tumors in the LSL-KRASG12D mouse model…ABT-263/selumetinib led to significantly greater tumor regression than either agent alone, and led to near-complete regression of tumors in some cases...
    DOI:
    10.1016/j.ccr.2012.11.007